Chronic inflammation is a well-known tumor-enabling capacity, which allows nascent tumors to acquire all the hallmark capabilities, including the escape from immunosurveillance. Soluble and cellular inflammatory mediators constitute the complex network of the tumor microenvironment, in which tumors grow and with which constantly interact. Myeloid cells (e.g., tumor associated macrophages) are pivotal players of the tumor microenvironment and are characterized by plasticity, which consists of the ability to acquire distinct phenotypes in response to the microenvironment in which they reside. Neutrophils are emerging as important players of tumor microenvironment, given their heterogeneity and plasticity. Increasing evidence suggests a dual role for neutrophils in modulating tumor behavior and highlights the need for a reassessment of neutrophil functions in cancer initiation and progression.
INTRODUCTION
Cancer-related inflammation (CRI) was already known for a long time, so that cancer was considered as "a wound that does not heal." 1 The presence of an immune infiltrate around tumors was largely attributed to an attempt of the immune system to eradicate cancer. During the last several decades, a growing number of observations have proved that CRI promotes tumor initiation and progression and enables cancer to acquire all hallmark capabilities, including the ability to evade immunosurveillance. 2 This new point of view emphasized the novel model that tumors should no longer be viewed merely as genetic diseases. Indeed, cancers initiate, progress, and respond to therapy within a complex microenvironment with which they continuously interact.
Tumor microenvironment (TME) is a complex network in which myeloid cells play pivotal roles in initiating and promoting cancer Abbreviations: 5-FU, 5-fluorouracil; BCG, bacillus Calmette-Guerin; CRC, colorectal cancer; CRI, cancer-related inflammation; G-MDSC, granulocytic myeloid-derived suppressor cell; HDN, high-density neutrophils; HNSCC, head and neck squamous cell carcinoma; LDN, low density neutrophils; MDSC, myeloid-derived suppressor cell; MMP, metalloprotease; NE, neutrophil elastase; NLR, neutrophil-to-lymphocyte ratio; NSCLC, non small cell lung cancer; PD-L1, programmed death-ligand 1; ROS, reactive oxygen species; sPLA 2 , secreted phospholipase; TANs, tumor-associated neutrophils; TME, tumor microenvironment development. Among tumor-infiltrating immune cells, macrophages are well-known players in CRI and are typically characterized by plasticity, that is, the ability to acquire a wide spectrum of activation states in response to the signals derived from the microenvironment. 3, 4 Beyond macrophages, neutrophils have recently been shown to play many roles in the various phases of cancer initiation and progression. 5 Indeed, they represent a surprisingly heterogeneous population, endowed with unsuspected plasticity. 6 In this review, we will recapitulate the main biological aspects of neutrophils and their roles in cancer development. We will evaluate their role(s) as prognostic and predictive biomarkers in human cancers and we will explore the functions of these tumor-infiltrating immune cells as means or targets of anticancer therapeutic approaches.
Roles of neutrophils in tumor growth and progression

1.1.1
Pro-tumor versus anti-tumor functions of neutrophils phenotype under the influence of TGF-. 7 Indeed, TGF-blockade led to the tumor infiltration of neutrophils with increased cytotoxicity, high expression of TNF-, CCL3, and ICAM-1, and low levels of arginase-1. TGF-inhibition also promoted a T-cell anti-tumor response, which involved neutrophils as effector cells. 7 Mirroring the M1/M2 paradigm, neutrophils were then proposed to polarize in two distinct activation states: an anti-tumor N1 or a pro-tumor N2 phenotype in response to signals derived from TME. In murine models of melanoma and fibrosarcoma, IFN-deletion favored the infiltration of neutrophils characterized by a high expression of CXCR4, VEGF-A, and metalloprotease 9 (MMP-9). 9 These results suggested a pivotal role for type I IFNs in polarizing neutrophils toward a N1 anti-tumoral phenotype. 6 However, to date, these findings were obtained only in murine models and the existence of polarized neutrophil populations still need to be demonstrated in humans.
Neutrophil recruitment in tumor microenvironment
Within the TME, CXC chemokines produced by tumor and stromal cells and associated with cancer growth and progression also retain neutrophil-recruiting functions. [10] [11] [12] For instance, human head and neck squamous cell carcinoma (HNSCC) cell lines produced CXCL8 and macrophage inhibiting factor, which induced neutrophil chemotaxis through the engagement of CXCR2. 13, 14 Hepatocellular carcinoma cells also recruited neutrophils through the production of CXCL8. 15 We recently found that thyroid cancer (TC) cells produce CXC chemokines, which were able to recruit neutrophils in a CXCR1/CXCR2-dependent manner (unpublished results). Moreover, TC-derived conditioned media were able to modify neutrophil biology, in terms of activation, modulation of survival, gene expression, and release of oxygen derivatives, suggesting an interesting role of tumorderived chemokines in influencing neutrophil plasticity.
Several experimental tumor models showed a central role for CXCR2 in promoting lung and pancreatic cancers. 16, 17 Indeed, CXCR2 deletion or neutrophil depletion suppressed inflammationinduced and spontaneous carcinogenesis in mice. 18 In addition, in a murine model of graft tumor, CXCL17 promoted cancer growth together with the increased infiltration of a myeloid subset of 19 In a conditional genetic murine model of lung cancer driven by K-ras activation and p53 inactivation, macrophages and neutrophils precursors accumulated in the spleen and relocated from the spleen to the tumor, suggesting a role for the spleen as reservoir for tumor-promoting myeloid cells. 20
Neutrophil-derived mediators in tumor growth
Neutrophils play important roles in tumor initiation. Indeed, neutrophils release oxygen and nitrogen free radicals, which promoted DNA point mutations and genetic instability. 21 Neutrophil granule proteins also play a dual role in tumor progression. Indeed, neutrophil elastase (NE) was taken up by lung cancer cells and degraded insulin receptor substrate-1, which usually inhibits PI3K.
This event unleashed PI3K activation and PDGFR signaling, thus favoring tumor cell proliferation. 22 NE was also involved in neutrophilrelated epithelial-to-mesenchymal transition. 23 By contrast, NE could also restrain antitumor immune response. In fact, NE taken up by breast cancer cells upregulated the expression of HLA class I in tumor cells, thus increasing the responsiveness of breast cancer cells to adaptive immunity. 24 Moreover, once taken up by breast cancer cells, NE cleaved cyclin E, which was then presented in a truncated form in HLA-I context and efficiently activated a CTL-mediated antitumor response. 25 Neutrophil-derived oncostatin M up-regulated VEGF production in breast cancer cells, promoting tumor cell detachment and invasiveness. 26 In bronchoalveolar carcinoma patients, hepatocyte growth factor in broncholavage fluid was correlated with neutrophil infiltration and was associated with poor prognosis. 27, 28 Neutrophils also release TRAIL, which retains important antitumoral activities. 29, 30 Indeed, Mycobacterium bovis bacillus CalmetteGuerin (BCG) induced the release of TRAIL from neutrophils, and this mechanism was proposed to play a role in the anticancer effects of BCG in human bladder cancer. 31 In addition, in chronic myeloid leukemia patients, the release of TRAIL from neutrophils induced by IFN-therapy promoted apoptosis of leukemic cells. 32, 33 In patients with early-stage lung cancer, a pro-inflammatory neutrophil phenotype, with high production of CCL2, CCL3, CXCL8, and IL-6, as well as high expression of costimulatory molecules (e.g., CD86
and OX40L) was found. These tumor-associated neutrophils (TANs) stimulated T-cell proliferation and IFN-release, mainly in a contactdependent manner 34 and amplified a positive feedback loop that suggested an anti-tumoral role for TANs in early stages of human lung tumor. 34 In a mouse model of PTEN-deficient uterine cancer, an inhibitory role for neutrophils was also described. Indeed, TANs inhibited earlystage tumor growth and retarded malignant progression by inducing tumor cell detachment from the basement membrane. TANs were recruited at tumor site independently of lymphocytes and cellular senescence but in the context of the tumor's intrinsic inflammatory response to hypoxia. In humans, a neutrophil gene signature correlated with improved survival in PTEN-deficient uterine cancer. 35 By contrast, in colorectal cancer (CRC) patients, an increased number of TANs (defined as "PMN-myeloid derived suppressor cells") were found, which were recruited and activated by tumor-infiltrating T cells, through the release of CXCL8/IL-8 and GM-CSF. These TANs produced high levels of arginase I and reactive oxygen species (ROS) and potently inhibited T-cell proliferation and IFN-production. 36
Pro-angiogenic versus anti-angiogenic functions of neutrophils
Neutrophils also play a dual role in modulating tumor angiogenesis. Neutrophils are main producers of VEGF-A and release high levels of MMP-9, which is responsible for the release of the active form of VEGF-A from the extracellular matrix. 15, 37, 38 Interestingly, neutrophils release MMP-9 in the absence of the inhibitor tissue inhibitor of proteases, thus further enhancing the pro-angiogenic and pro-invasive activity of MMP-9. 39 By contrast, in a murine model of breast cancer, intratumoral delivery of MMP-9 reduced tumor growth and angiogenesis, suggesting that MMP-9 also retains anti-angiogenic functions. 40 In a xenograft murine model, under the influence of G-CSF, neutrophils released the pro-angiogenic molecule Bv8. 41 Interestingly, tumors resistant to anti-VEGF therapy showed high infiltration of neutrophils and drug resistance was associated with G-CSF-induced Bv8 neutrophil expression. 42, 43 Neutrophils also express a number of anti-angiogenic molecules.
For example, NE cleaved VEGF and FGF-2, giving rise to the angiostatin-like fragments from plasminogen, which suppressed VEGF-and FGF-2-induced angiogenesis. 44, 45 We found that exogenous Group V (hGV) and Group X (hGX) secreted phospholypases 
High-density versus low-density neutrophils and MDSCs
An increasing number of observations have highlighted the surprising plasticity and heterogeneity of neutrophils, in humans and in experimental cancer models. Indeed, peripheral blood human neutrophils are usually purified on a discontinuous density gradient (Ficoll). Following this separation, neutrophils segregate in the high-density granulocytic fraction, whereas peripheral blood mononuclear cells (PBMC) are found in the low-density (LD) mononuclear fraction. 51 However, in chronic inflammatory conditions such as HIV infection, autoimmunity and cancer, neutrophils can be also found in the LD fraction. [52] [53] [54] [55] This proportion of low density neutrophils (LDNs) increases with cancer progression, displays T-cell suppressive functions, and is represented by both mature and immature granulocytes. 56 57, 58 In previous papers, some authors described G-MDSCs as immature myeloid cells, which inhibited CD8 + T-cell mediated anti-tumor immune response through the release of arginase I. 59 By contrast, several authors described these cells as a subpopulation of activated degranulated neutrophils, inhibiting T-cell response through the release of arginase I 54,60 or ROS. 55 Transcriptomic analysis performed on naive neutrophils, TANs, and G-MDSC in tumor-bearing mice found that TANs and G-MDSC are distinct populations 61 and that naïve neutrophils and G-MDSC are more closely related to each other than to TANs. 62 
Neutrophils as prognostic/predictive biomarkers in cancer patients
The relationship between TANs and prognosis in human cancers has been already extensively discussed. 64 Neutrophil infiltration within human tumors was correlated with poor patient outcome in metastatic and localized clear cell carcinomas, bronchioloalveolar, liver, uterine cervical cancer, colorectal (CRC), and HNSCC. 15, 27, [65] [66] [67] [68] In addition, neutrophil infiltration was associated with high tumor grade in human gliomas and with aggressive pancreatic tumors. 69, 70 Recently, among the tumor-infiltrating cells, neutrophils were found the most prevalent immune cell type in non small cell lung cancer (NSCLC) tissues, negatively correlated with tumor-infiltrating CD8 + , CD4 + , Th1, and Th17 cells and efficiently predicted patient mortality. 71, 72 By contrast, TANs were associated with good patient prognosis in gastric 73 An important task will be to investigate the predictive role of TANs in cancer patients. In the only published study, performed on Stage III CRC patients, TAN infiltration was associated with better response to 5-fluorouracil (5-FU) based chemotherapy but with poor prognosis in patients treated with surgery alone. 74 These results suggest a dual clinical significance of TANs, depending on the administration of chemotherapy and highlight the need for a re-evaluation of the role of TANs as predictive factors for response to therapy in human cancers. 74 Several studies have evaluated the prognostic and predictive value of neutrophil-to-lymphocyte ratio (NLR) in peripheral blood of cancer patients. NLR is considered an indicator of systemic inflammation and predicted patient clinical outcome in several human cancers, such as rectal, 76 esophageal, 77 prostate, 78 pancreatic, 79 and breast cancer. 80 Moreover, a high NLR score was associated with worst survival and displayed a more consistent prognostic value among patients with advanced disease. 81 The advantage of this score is that it can be easily measured. However, its prognostic power is controversial.
Indeed, NLR is not a specific biomarker since it can be confounded by other variables that influence the count of peripheral blood neutrophils and/or lymphocytes. 82 Moreover, since circulating neutrophils are not a homogeneous population, the mere count could not be a reliable biomarker of their biological functions in cancer patients. In addition, circulating neutrophils may not faithfully mirror the tumorrelated ones. Thus, further studies aimed at investigating circulating neutrophil-related markers that more likely reflect the TME are needed to identify more specific biomarkers in cancer patients.
Neutrophils in anticancer therapeutic responses
Myeloid cells can influence the effectiveness of chemotherapeutic regimens. Indeed, chemotherapeutic drugs exert their effects not only acting on tumor cells, but also on tumor-related immune cells. Indeed, some chemotherapeutic drugs, such as doxorubicin, determine an "immunogenic cell death": tumor cell death induces the expression of "danger signals" (i.e., calreticulin, ATP, and HMGB-1), which recruit and activate myeloid DC-like cells. These cells are particularly efficient in capturing and presenting tumor cell antigens and give rise to an effective anti-tumor immune response. 83, 84 Immunotherapy with checkpoint inhibitors is an established part of the therapeutic strategies for an increasing number of solid and hematologic tumors. 85 Recent evidence indicates that programmed death-ligand 1 (PD-L1) is also expressed on neutrophils and is associated with the development of numerous diseases, including HIV, 86 sepsis, 87 Burkholderia pseudomallei infected disease, 88 tuberculosis, 89 and autoimmunity. 90 Recently, neutrophils accumulating in gastric cancer tissues displayed a prolonged survival, an activated phenotype, and high levels of PD-L1 expression. Increased infiltration of PD-L1 + neutrophils was associated with disease progression and poor patient survival. Moreover, neutrophils purified from peripheral blood of healthy donors in vitro up-regulated PD-L1 when stimulated with gastric cancer cell line conditioned media. Finally, activated PD-L1 + neutrophils inhibited the proliferation and activation of T cells, dampening antitumor T-cell-mediated adaptive response to promote gastric cancer. 91 Since neutrophils can retain tumor-promoting functions, targeting these cells could be desirable. However, their depletion could lead to deleterious "side effects". Indeed, neutrophils play a central role in host defense against pathogens and their depletion could lead to immunosuppression. Neutrophil neutralization could be obtained by inhibiting their recruitment or their effector molecules. In a murine model of fibrosarcoma and prostate cancer, the inhibition of TAN recruitment through CXCL8/IL-8 blockage reduced tumor growth and angiogenesis. 92 In addition, in multiple murine models of inflammationdriven and spontaneous carcinogenesis, genetic or pharmacologic abrogation of CXCR2 inhibited tumor development. 18 Repertaxin, a small inhibitor of CXCR1 and CXCR2, selectively targeted human breast cancer stem cells and inhibited tumor growth in xenograft murine models. 93 The combination of repertaxin and 5-FU increased gastric cancer cell apoptosis and inhibited proliferation, migration, and invasion. 94 Clinical trials investigating the role of repertaxin in breast cancer patients, alone or in combination with chemotherapeutic drugs (paclitaxel), are in progress (www.clinicaltriasl.gov).
The inhibitor of NE sivelastat inhibited breast cancer cell proliferation and enhanced the anti-tumor effect of trastuzumab through restoring the expression of Her2/Neu. 95 Genetic deficiency and inhibition of NE reduced the incidence of ultraviolet B-induced tumors in mice. 96 The NE inhibitor ONO-5046 reduced both primary and metastatic growth of NSCLC in severe combined immunodeficiency mice. 97 NE inhibitors are currently undergoing clinical trials for treatment of cystic fibrosis and respiratory diseases (www.clinicaltrials.gov) and these results could also be useful for cancer research.
A neutrophil-based drug delivery system has been proponed in a murine model of glioblastoma. Interestingly, neutrophils were loaded with a cationic liposome containing paclitaxel (PTX-CL) and were injected intravenously in tumor-bearing mice after surgical removal of the primary tumor. After injection, neutrophils homed to the surgical margins where inflammatory cytokines were abundant, and released PTX-CL, giving rise to a high local delivery of PTX. By this therapeutic approach, tumor cells were killed and glioma recurrence was delayed. Despite its limitations, this study shows that neutrophils could be successfully harnessed to deliver drugs into the brain across the blood/brain barrier. 98 
CONCLUSIONS
Cellular and humoral components of TME play important roles in cancer initiation and progression and in the response of most tumors to 
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